Results of Annual General Meeting

Jun 12, 2024

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 1866S
Advanced Medical Solutions Grp PLC
12 June 2024
 

12 June 2024

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company’s Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 13 May 2024.

 

The poll results were as follows.

 

Resolution

Title

For

For %

Against

Against %

Total Votes

% Issued Capital

1

FINANCIAL STATEMENTS

         136,356,167

99.99%

                   9,361

0.01%

       136,365,528

62.69%

2

REMUNERATION REPORT

         134,014,363

98.45%

             2,107,730

1.55%

       136,122,093

62.58%

3

AUDITOR REMUNERATION

         133,257,997

97.65%

             3,210,036

2.35%

       136,468,033

62.74%

4

RE-ELECT L SHANAHAN

         129,648,691

95.22%

             6,506,705

4.78%

       136,155,396

62.60%

5

RE-ELECT G COOK

         129,863,105

95.16%

             6,601,163

4.84%

       136,464,268

62.74%

6

RE-ELECT D LE FORT

         130,840,531

95.88%

             5,623,737

4.12%

       136,464,268

62.74%

7

RE-ELECT C MEREDITH

         132,798,078

97.31%

             3,666,187

2.69%

       136,464,265

62.74%

8

RE-ELECT E JOHNSON

         136,218,616

99.82%

                245,652

0.18%

       136,464,268

62.74%

9

FINAL DIVIDEND

         136,505,565

100.00%

                      516

0.00%

       136,506,081

62.76%

10

Deferred Bonus Plan

         136,377,375

99.92%

                113,837

0.08%

       136,491,212

62.75%

11

Long Term Incentive Plan

         135,984,889

99.63%

                506,310

0.37%

       136,491,199

62.75%

12

Deferred Share Bonus Plan

         136,190,086

99.78%

                300,213

0.22%

       136,490,299

62.75%

13

ALLOT SHARES*

         135,883,826

99.56%

                600,189

0.44%

       136,484,015

62.75%

14

PRE-EMPTION RIGHTS*

         134,775,458

98.75%

             1,708,671

1.25%

       136,484,129

62.75%

15

PURCHASE SHARES*

      108,148,575

99.92%

                 82,427

0.08%

       108,231,002

49.76%

*  Special Resolution

Notes:

1.  Votes “For” and “Against” are expressed as a percentage of votes received.

2.  A “Vote withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

3.  Total number of shares in issue at close of business on 7 June = 217,508,089 shares. 62.75% of the voting capital was instructed.

 

End –

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

ICR Consilium

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone

AMS@icrhealthcare.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

HSBC Bank plc (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made six acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, and Syntacoll, a German specialist in collagen-based absorbable surgical implants.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see  www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

RAGSFWFEEELSELM

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.